Physician profile
Adelaida Bustos
NPI 1467510040
$1,827.08
in general payments reported to CMS, 2019-2025
13 companies · $371 in 2025
The $371 reported for 2025 was more than what 76% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.70 · 2020: $250 · 2021: $412 · 2022: $325 · 2023: $241 · 2024: $192 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $598.13 | 2019-2025 | Zoryve, Livalo |
| Amarin Pharma, INC. | $375.73 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.45 | 2020-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $150.00 | 2025 | |
| Novo Nordisk INC | $124.87 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $110.98 | 2023-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $67.00 | 2021 | |
| Merck Sharp & Dohme LLC | $62.19 | 2021-2024 | Vaxelis, Vaxneuvance, Gardasil |
| Medtronic, INC. | $42.87 | 2023 | Intellis Adaptivestim |
| Exact Sciences Corporation | $42.50 | 2023 | Cologuard Collection Kit |
| Becton, Dickinson and Company | $28.02 | 2022-2024 | Bd Onclarity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.76 | 2024 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $15.58 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adelaida Bustos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.